Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (<0.8 U/ml → non-reactive), respectively. The patient was diagnosed with COVID-19 reinfection and DM. The patient was treated with convalescent plasma, antivirus, antibiotics, insulin, steroid, anticoagulant, and other symptomatic medications. As the results, a well improvement of his clinical condition and the increase of Ab COVID-19 IgM and IgG evaluation test after convalescent plasma administration, 0.28 AU/ml and 17.67 AU/ml, respectively, were recorded. Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM.
| Published in | American Journal of Internal Medicine (Volume 10, Issue 2) |
| DOI | 10.11648/j.ajim.20221002.11 |
| Page(s) | 20-27 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Coronavirus, COVID-19 Reinfection, Diabetes Mellitus, Antibody, Antibody Titer
| [1] | Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The pathogenesis of coronavirus disease 2019 (COVID-19): evaluation and prevention. Hindawi Journal of Immunology Research. 2020; 1-7. |
| [2] | Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020; 87 (4): 281-286. |
| [3] | Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. 2020. The New England Journal of Medicine. 2020.382: 1708-20. |
| [4] | World Health Organization. WHO Coronavirus (COVID-19) Dashboard. WHO. 2022. Available at: https://COVID19.who.int/region/searo/country/id Accessed [Feb 2022]. |
| [5] | Suryahadi A, Izzati RA, Suryadarma D. The impact of COVID-19 outbreak on poverty: an estimation for Indonesia. 2020. The SMERU Research Institute Publications. |
| [6] | Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, et al. Impact of COVID-19 pandemic on utilization of healthcare services: a systematic review. British Medical Journal. 2021; 11 (3): e045343. |
| [7] | World Health Organization. COVID-19 disrupting mental health services in most countries, WHO Survey. WHO. 2020. Available at: https://www.who.int/news/item/05-10-2020-COVID-19-disrupting-mental-health-services-in-most-countries-who-survey Accessed [Feb 2022]. |
| [8] | World Health Organization. Impact of COVID-19 on people’s livelihoods, their health and our food systems. WHO. 2020. Available at: https://www.who.int/news/item/13-10-2020-impact-of-COVID-19-on-people's-livelihoods-their-health-and-our-food-systems#:~:text=The%20economic%20and%20social%20disruption,the%20end%20of%20the%20year. Accessed [Feb 2022]. |
| [9] | Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal 2020: 2000547. |
| [10] | Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069. |
| [11] | Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metabolism Research and Reviews. 2020: e3319. |
| [12] | Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes & Metabolic Syndrome. 2020; 14 (4): 535-545. |
| [13] | Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323 (20): 2052-2059. |
| [14] | Lanstra CP, Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Frontiers in Endocrinology. 2021; 12 (6496250): 1-18. |
| [15] | Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020; 14: 303-10. |
| [16] | Guo X, Meng G, Liu F, Zhang Q, Liu L, Wu H, et al. Serum levels of immunoglobulins in an adult population and their relationship with type 2 diabetes. Diabetes Research and Clinical Practice. 2016: 76-82. |
| [17] | Pal R, Banerjee M. Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19?. Primary Care Diabetes Europe. 2021: 18-20. |
| [18] | Lafaie L, Célarier T, Goethals L, Pozzeto B, Sylvain G, Ojardias E, et al. Recurrence or relapse of COVID-19 in older patients: a description of three cases. Journal of the American Geriatrics Society. 2020: 68 (10): 2179-2183. |
| [19] | Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: a report of two cases. Journal of Infection. 2020; 81 (2): e72-e73. |
| [20] | Zare F, Teimori M, Khosravi A, Rohani-Rasaf M, Chaman R, Hosseinzadeh A. COVID-19 reinfection in shahroud, Iran; a follow up study. Epidemiology and Infection. 2021; 19: 1-12. |
| [21] | Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. 2016: 351 (2); 201-211. |
| [22] | Pal R, Bhansali A. COVID-19, diabetes mellitus, and ACE2: the conundrum. Diabetes Research & Clinical Practice. 2020; 162: 108132. |
| [23] | Zhou W, Ye S, Wang W, Li S, Hu Q. Clinical features of COVID-19 patients with diabetes and secondary hyperglycemia. Journal of Diabetes Research. 2020.3918723. |
| [24] | Ugwueze CV, Ezeokpo BC, Nnolim BI, Agim EA, Anikpo NC, Onyekachi KE. COVID-19 and diabetes mellitus: the link and clinical implications. Dubai Diabetes Endocrinology Journal. 2020; 26: 69-77. |
| [25] | Mishra Y, Pathak BK, Mohakuda SS, et al. Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. Diabetes & Metabolic Syndrome. 2020; 14 (6): 1927-1930. |
| [26] | Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020; 14: 513-517. |
| [27] | Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetic of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging Microbes & Infection. 2020; 9 (1): 940-948. |
| [28] | Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020. 2020; 369 (6505): 818-823. |
| [29] | To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 2020; 20 (5): 565-574. |
| [30] | Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv. 2020. |
| [31] | Pal R, Sachdeva N, Mukherjee S, Suri V, Zohmangaihi D, Ram S, et al. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021; 15 (1): 193-196. |
| [32] | Pavlou S, Lindsay J, Ingram R, Xu H, Chen M. Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity. BMC Immunology. 2018; 19: 24. |
| [33] | Sireesh D, Dhamodharan U, Ezhilarasi K, Vijay V, Ramkumar KM. Association of NF-E2 Related Factor 2 (Nrf2) and inflammatory cytokines in recent onset Type 2 Diabetes Mellitus. Scientific Reports. 2018; 8: 5126. |
| [34] | Martinez PJ, Mathews C, Actor JK, Hwang S, Brown EL, De Santiago HK, et al. Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumonia is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus. Transl Res. 2014; 163 (1): 53-63. |
| [35] | Peleg AY, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes: pathogenesis, management and relationship to glycemic control. Diabetes Metabolism Research & Reviews. 2007; 23: 3-13. |
| [36] | Jennbacken K, Stahlman S, Grahnemo L, Wiklund O, Fogelstrand L. Glucose impairs B-1 cell function in diabetes. Clinical & Experimental Immunology. 2013; 174 (1): 129-138. |
| [37] | Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes & Metabolisme. 1992; 18 (3): 187-201. |
| [38] | Volti SL, Caruso-Nicoletti M, Biazzo F, Sciacca A, Mandara G, Mancuso M, Mollica F. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child. 1998; 78: 54-57. |
| [39] | Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care. 2000; 23 (1): 95-108. |
| [40] | Simonovich VA, Pratx LDB, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. The New England Journal of Medicine. 2021: 384 (7); 619-629. |
| [41] | Agarwal A, Mukherjee A, Kumar G, Chatterje P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicenter randomized controlled trial (PLACID Trial). BMJ. 2020; 371. |
| [42] | Libster R, Marc GP, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. The New England Journal of Medicine. 2021; 384 (7): 610-618. |
| [43] | Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. The New England Journal of Medicine. 2021; 384: 1015-1027. |
| [44] | COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at https://www.COVID19treatmentguidelines.nih.gov/. Accessed [Aug 2021]. |
| [45] | Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases. 2020; 102: 501-508. |
| [46] | Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific Reports. 2021; 11: 11022. |
| [47] | Oliver ME, Hinks TSC. Azithromycin in viral infections. Reviews in Medical Virology. 2021; 31 (2): e2163. |
| [48] | Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, Cusco MD, Ferrandez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Review of Anti-Infective Therapy. 2021; 19 (2): 147-163. |
| [49] | PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomized, controlled, open-label, adaptive platform trial. The Lancet. 2021; 397 (10279); 1063-1074. |
| [50] | Nestler MJ, Godbout E, Lee K, Kim J, Noda AJ, Taylor P, et al. Impact of COVID-19 on pneumonia-focused antibiotic use at an academic medical center. Cambridge University Press Public Health Emergency Collection. Infection Control & Hospital Epidemiology. 2020; 23: 1-3. |
| [51] | Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020; 191: 145-147. |
| [52] | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395 (10229): 1054-1062. |
| [53] | Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology. 2020; 75 (18): 2352-2371. |
| [54] | American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. 2020. Available at: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patientswith-COVID-19. Accessed [Aug 2020]. |
| [55] | Royal College of Physicians. Clinical guide for the prevention, detection and management of thromboembolic disease in patients with COVID-19. 2020. Available at: https://icmanaesthesiaCOVID-19.org/clinical-guide-preventiondetection-and-management-of-vte-in-patients-with-COVID-19. Accessed [Aug 2021]. |
| [56] | Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis. 2020; 50 (1): 72- 81. |
| [57] | Marietta M, Ageno W, Artoni A, Candia ED, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion. 2020; 18 (3): 167-169. |
| [58] | Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020; 18 (5): 1023-1026. |
| [59] | Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020; 158 (3): 1143-1163. |
| [60] | RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. The New Englang Journal of Medicine. 2021; 384 (8): 693-704. |
| [61] | WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324 (13): 1330-1341. |
| [62] | Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020; 324 (13): 1307-1316. |
| [63] | Schönbeck U, Libby P. Inflammation, immunity, and HMGCoA reductase inhibitors: statins as anti-inflammatory agents? Circulation. 2004; 109 (21 Suppl 1): II18-26. |
| [64] | Reiner Z, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Statins and the COVID-19 main protease: in silico evidence on direct interacton. Archives of Medical Science. 2020; 16 (3): 490-496. |
| [65] | Castiglione V, Chiriaco M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. European Heart Journal – Cardiovascular Pharmacotherapy. 2020; 6 (4): 258-259. |
| [66] | Chow R, Im J, Chiu N, Chiu L, Aggarwal R, Lee J, et al. The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2021; 16 (6): e0253576. |
| [67] | Daniels LB, Ren J, Kumar K, Bui QM, Zhang J, Zhang X, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry. PLoS ONE. 2021; 16 (7): e0254635. |
| [68] | Fisher BJ, Seropian IM, Kraskaukas D, Thakkar JN, Voelkel NF, Fowler AA, Natarajan R. Ascorbic acid attenueated lipopolysaccharide-induced acute lung injury. Critical Care Medicine. 2011; 39 (6): 1454-1460. |
| [69] | Wei XB, Wang ZH, Liao XL, Guo WX, Wen JY, Qin TH, Wang SH. Efficacy of vitamin C in patients with sepsis: an updated meta-analysis. European Journal of Pharmacology. 2020; 868: 172889. |
| [70] | Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptoms length and reduction among ambulatory patients with SARS-CoV-2 infection: The COVID A to Z randomized clinical trial. JAMA Network Open. 2021; 4 (2): e210369. |
| [71] | Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. Journal of Medical Virology. 2020; 92 (5): 479-490. |
| [72] | Rossetti CA, Real JP, Palma SD. High dose of ascorbic acid used in Sars COVID-19 treatment: scientific and clinical support for its therapeutic implementation. Ars Pharmaceutica. 2020; 61 (2): 145-148. |
| [73] | Elhidsi M, Fachrucha F, Irawan RY. N-acetylcysteine for coronavirus disease-19: a potential adjuvant therapy. Journal of Health Science. 2021; 11 (1): 1-6. |
| [74] | Shi Z, Puyo CA. N-acetylcysteine to combat COVID-19: An evidence review. Therapeutics and Clinical Risk Management. 2020; 16: 1047-1055. |
| [75] | Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of n-acetylcysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. European Review for Medical and Pharmacological Sciences. 2021; 25 (6): 2802-2807. |
| [76] | Poe FL, Corn J. N-acetylcysteine: a potential therapeutic agent for SARS-CoV-2. Med Hypotheses. 2020; 143: 109862. |
| [77] | Atefi N, Behrangi E, Mozafarpoor S, Sierafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. Journal of Research in Medical Sciences. 2020; 25: 109. |
| [78] | De Alencar JCG, Moreira CdL, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, randomized, placebo-controlled trial with n-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021; 72 (11): e736-e741. |
| [79] | Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clinical Medicine (London). 2020; 20 (4): e107-e108. |
| [80] | Teshome A, Adane A, Girma B, Mekonnen ZA. The impact of vitamin D level on COVID-19 infection: systematic review and meta-analysis. Frontiers in Public Health. 2021; 9: 624559. |
| [81] | Fisher SA, Rahimzadeh M, Brierley C, Gration B, Doree C, Kimber CE, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review. PLoS One. 2019; 14 (9): e0222313. |
| [82] | Murai IH, Fernanded AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021; 325 (11): 1053-1060. |
| [83] | Bassatne A, Basbous M, Chakhtoura M, Zein OE, Rahme M, Fuleihan GEH. The link between COVID-19 and vitamin D (VIVID): A systematic review and meta-analysis. Metabolism: clinical and experimental. 2021; 119: 154753. |
APA Style
Albert William Hotomo, Heri Sutrisno Prijopranoto. (2022). COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia: A Case Report. American Journal of Internal Medicine, 10(2), 20-27. https://doi.org/10.11648/j.ajim.20221002.11
ACS Style
Albert William Hotomo; Heri Sutrisno Prijopranoto. COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia: A Case Report. Am. J. Intern. Med. 2022, 10(2), 20-27. doi: 10.11648/j.ajim.20221002.11
AMA Style
Albert William Hotomo, Heri Sutrisno Prijopranoto. COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia: A Case Report. Am J Intern Med. 2022;10(2):20-27. doi: 10.11648/j.ajim.20221002.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20221002.11,
author = {Albert William Hotomo and Heri Sutrisno Prijopranoto},
title = {COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia: A Case Report},
journal = {American Journal of Internal Medicine},
volume = {10},
number = {2},
pages = {20-27},
doi = {10.11648/j.ajim.20221002.11},
url = {https://doi.org/10.11648/j.ajim.20221002.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221002.11},
abstract = {Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM.},
year = {2022}
}
TY - JOUR T1 - COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia: A Case Report AU - Albert William Hotomo AU - Heri Sutrisno Prijopranoto Y1 - 2022/03/03 PY - 2022 N1 - https://doi.org/10.11648/j.ajim.20221002.11 DO - 10.11648/j.ajim.20221002.11 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 20 EP - 27 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20221002.11 AB - Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM. VL - 10 IS - 2 ER -
Information
Email: